Genocury Biotech Announces Groundbreaking Advance in Relapsed/Refractory DLBCL Through Pioneering In Vivo CD19 CAR-T Therapy
Press Releases
Genocury Biotech  
May 2, 2025

Genocury Biotech Announces Groundbreaking Advance in Relapsed/Refractory DLBCL Through Pioneering In Vivo CD19 CAR-T Therapy

Genocury launched the in vivo CD19 CAR-T therapy to reach the clinical stage, demonstrating exceptional safety, efficiency and durability.

logo salamanca press

Salamanca Press

Local & Social